摘要随着我国新生儿医学的发展,早产儿、低体重儿的存活率明显提高,早产儿视网膜病变(ROP)的发病率出现逐年上升的趋势.ROP严重时可导致失明,是我国目前儿童盲的首位原因,对家庭和社会造成沉重负担.近年来随着对ROP发病机制的深入了解,ROP治疗不断拓展,尤其抗血管内皮生长因子(VEGF)治疗取得了令人鼓舞的治疗效果.但是目前抗VEGF药物治疗ROP仍属于超适应证用药,并且其有效性和安全性、给药剂量、随访时间等仍需要探索,因此本文提出临床仍需谨慎开展抗VEGF药物治疗ROP.

abstractsWith the rapid development of perinatology in China and the implementation of the two-child policy,the survival rate of premature and low weight infants is obviously improved,and the incidence of retinopathy of prematurity (ROP) in preterm infants has been increasing year by year.ROP can lead to blindness when it is serious.It is the first cause of blindness of children in our country,and it is a heavy burden on family and society.With novel insights in the pathogenesis of the disease,anti-vascular endothelial growth factor pharmacotherapy has blated its way into ophthalmological practice and significantly changed the management of ROP.However,facing such promising drugs,we still need to take caution with the safety and long-time efficacy,investigate more reasonable dosing schedules and study the follow-up time.